T Matthes
Overview
Explore the profile of T Matthes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
182
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grandclement C, Estoppey C, Dheilly E, Panagopoulou M, Monney T, Dreyfus C, et al.
Nat Commun
. 2024 Mar;
15(1):2054.
PMID: 38448430
Antibody engineering can tailor the design and activities of therapeutic antibodies for better efficiency or other advantageous clinical properties. Here we report the development of ISB 1442, a fully human...
2.
Lacombe F, Bernal E, Bloxham D, Couzens S, Porta M, Johansson U, et al.
Leukemia
. 2016 Mar;
30(8):1769-72.
PMID: 26922887
No abstract available.
3.
Matthes T, Manfroi B, Zeller A, Dunand-Sauthier I, Bogen B, Huard B
Leukemia
. 2015 Jul;
29(9):1882-90.
PMID: 26159051
Multiple myeloma (MM) invariably develops in the bone marrow (BM), indicating the strong requirement of this tumor for the peculiar BM microenvironment, rich in cytokine and hematopoietic precursor cells. Interleukin-6...
4.
Matthes T, McKee T, Dunand-Sauthier I, Manfroi B, Park S, Passweg J, et al.
Leukemia
. 2015 Mar;
29(9):1901-8.
PMID: 25753925
Multiple myeloma (MM) is a non-curable tumor developing in the bone marrow (BM). The BM microenvironment rich in hematopoietic precursors is suspected to have a role in MM development. Here...
5.
Taverna C, Bargetzi M, Betticher D, Gmur J, Gregor M, Heim D, et al.
Swiss Med Wkly
. 2010 May;
140:w13054.
PMID: 20458652
The treatment of multiple myeloma has undergone significant changes in the recent past. The arrival of novel agents, especially thalidomide, bortezomib and lenalidomide, has expanded treatment options and patient outcomes...
6.
Burjanadze M, Matthes T, McKee T, Passweg J, Huard B
Histol Histopathol
. 2009 Jun;
24(8):1061-6.
PMID: 19554513
A proliferation inducing ligand (APRIL) is one of the most recently cloned members of the tumor necrosis factor (TNF) family. Early experiments implicated a pathophysiological role for APRIL in the...
7.
Roosnek E, Burjanadze M, Dietrich P, Matthes T, Passweg J, Huard B
Crit Rev Oncol Hematol
. 2009 Mar;
72(2):91-7.
PMID: 19286389
Inflammatory cells produce a proliferation inducing ligand (APRIL), one of the most recently cloned members of the tumor necrosis factor (TNF) family. Early experiments implicated APRIL as a promoting factor...
8.
Passweg J, Chalandon Y, Matthes T, Beris P, Aapro M, Plan P
Rev Med Suisse
. 2008 Jul;
4(158):1272-4, 1276-8.
PMID: 18616210
No abstract available.
9.
Ody C, Jungblut-Ruault S, Cossali D, Barnet M, Aurrand-Lions M, Imhof B, et al.
Leukemia
. 2007 Apr;
21(6):1285-93.
PMID: 17429428
Differentiation of naïve B cells into plasma cells or memory cells occurs in the germinal centers (GCs) of lymph follicles or alternatively via a GC- and T-cell-independent pathway. It is...
10.
Durual S, Rideau A, Ruault-Jungblut S, Cossali D, Beris P, Piguet V, et al.
Leukemia
. 2007 Mar;
21(5):1050-9.
PMID: 17361223
PU.1, a transcription factor of the ETS family, plays a pivotal role in normal hematopoiesis, and particularly in myeloid differentiation. Altered PU.1 function is possibly implicated in leukemogenesis, as PU.1...